Clot-related adverse events in VAERS 60 days out from last shot
Modified mRNA LNP products versus 'traditional' vaccines
When we wrote up the updated myocarditis paper1, we had an idea to include examples of individuals who had succumbed to myocarditis many months after their last injection of COVID-19 injectable product, as per their reports to VAERS. In both cases included our paper, the product was Pfizer. As you can see in Figure 1 below, a 15-year-old boy had a diagnosis of idiopathic myocarditis that resulted in death 358 days after his first, and last, Pfizer injection.
This is shocking enough, and these are only two examples. These late occurrences of myocardial incidents left me thinking about the long-term effects of these modified mRNA COVID-19 products.
I was more recently prompted to examine clot-related adverse events (AEs) in VAERS, since the lipid nanoparticles (LNPs) are suspected to be - along with the spike protein - a root cause of hemagglutination. I gave a talk about all things LNP to Doctors for COVID Ethics last year, and you can watch that here. I think they disrupt the zeta potential of red blood cells, as does the spike protein.23
We all know by now, especially by the given name “clot shot”, that the COVID-19 shots are associated with thrombotic events and clotting in human beings. It is widely accepted now also that SARS-2 itself is not a respiratory pathogen, but one that can induce these same clotting issues in people, and thus these ‘symptoms’ are certainly spike-related. But again, the LNPs don’t help and without them, the modified mRNA would likely get degraded way before it could ever be translated into ‘spike’ protein if not protected by the LNP trojan horse.
I pulled out clot-related4 AEs reported to VAERS in the domestic data associated with the modified mRNA shots reported from 2021 through to 2023. I did the same thing for all vaccines through 2018-2020. And similarly, for the Janssen and Novavax products for 2021-2023 in order to compare modified mRNA products and non-modified mRNA products.5 For each group, I separated out the reports that were made 60 days or more from the last injection. I suspected that in the context of the modified mRNA shots that there would be many more reports post 60 days than for ‘regular’ vaccines, and maybe for the non-modified mRNA products, since they do not employ this non-limiting, self-producing spike technology wrapped in these likely-degraded fat bubbles. Here’s what I found in what I fondly will call the “clot plots”. I will start with a comparison between all vaccines and the modified mRNA COVID-19 products (Figure 3).
It is quite striking isn’t it? Indeed, the number of shots administered for all vaccines combined is higher6 than for the number of modified mRNA COVID-19 shots for these 3 year periods, yet, the clot-related AEs differ in absolute count quite a bit. It seems like the ‘traditional’ vaccines don’t induce clotting in quite the same way as the LNP-spike-based products. So is it the LNPs? Or is it the spike?
Let’s look at the J&J and Novavax shots compared to the modified mRNA shots. Nota bene: the Novavax shots represent only 0.6% of all the reports when clumping the non-modified mRNA shots together (ie: Janssen and Novavax), so when I write about Janssen and Novavax together, I am basically only referring to Janssen.
Approximately 14% of all clot-related reports in the context of the modified mRNA products were made 60 days out whereby only ~5 and ~7% of reports made for all vaccines and the non-modified mRNA products were made 60 days out, respectively.
There were far fewer Janssen/Novavax shots doled out all-in-all, and interestingly, relative to the total AE count per manufacturer, Janssen is the worst for clotting. But… When does the clotting take place?
When the post-60-day data is normalized per 100,000 clot reports as per manufacturing type (modmRNA vs non-modmRNA), it is clear that Houston, we have a clotting problem with the modified mRNA products when it comes to a delayed reporting effect. Therefore, even though the Janssen (and Novavax) products may induce clotting with immediate effects, the modified mRNA products appear to induce reportable clotting effects months after the last dose.
The difference between the percentages of clot-related 60-day-out reports is notable when comparing the modified mRNA and non-modified mRNA shots. 13.7% of the modified mRNA clot-related reports occurred 60 days out from the last shot, and in the case of all vaccines combined and the Janssen/Novavax products, they stand somewhat equal at 5.2% and 7.6% - far below the percentage reported for their modified mRNA colleagues.
Conclusion
The modified mRNA injectable COVID-19 products appear to induce clotting months after a ‘last’ shot, according to VAERS reports. It is notable that of these post-60-day reports, 69% were filed by medical professionals, so it was the opinion of these medical professionals that it was worth filing these clot-related reports months after their patient’s last COVID shot and therefore, they likely suspected a causal relationship. Proper ‘ting, as we Newfoundlanders say.
Rose J, Hulscher N, McCullough PA. Determinants of COVID-19 vaccine-induced myocarditis. Ther Adv Drug Saf. 2024 Jan 27;15:20420986241226566. doi: 10.1177/20420986241226566. PMID: 38293564; PMCID: PMC10823859
Scheim, D.E. A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody. Int. J. Mol. Sci. 2022, 23, 2558. https:// doi.org/10.3390/ijms23052558
Boschi C, Scheim DE, Bancod A, Militello M, Bideau ML, Colson P, Fantini J, Scola BL. SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects. International Journal of Molecular Sciences. 2022; 23(24):15480. https://doi.org/10.3390/ijms232415480
keywords used: ‘clot’, ‘occlusion’ and ‘agglutination’
Nota bene: the Novavax shots represent only 0.6% of all the reports when clumping the non-modified mRNA shots together (ie: Janssen and Novavax), so when I write about Janssen and Novavax together, I am basically only referring to Janssen. I didn’t want to exclude Novavax completely, but with regards to this analysis, Novavax is pretty irrelevant.
I was shocked to discover that msost of the ‘vaccine’ coverage data has been removed from the CDC website: https://covid.cdc.gov/covid-data-tracker/#vaccine-delivery-coverage
Incredible chart now lay on top of that the under reporting in the VAERS system yes we do have a clotting problem Houston thanks again Dr Jessica Rose 🌹
Dr John Campbell had a very interesting video with a vascular surgeon his name escapes me at this time , an actually surgery was shown on the carotic vein in the patient’s neck and what he pulled out is freaking scary
My husband died 65 days after the j jab. Double massive pulmonary embolisms in a perfectly healthy man with zero history of clotting issues (none in his family either).
They gave him heparin in the ER, which led to him yelling “I can’t breathe”, then about 1 minutes later he was yelling “I’m dying” for another minute then collapsed. THEN the ER gave him the clot blaster drug. 43 minutes of CPR later, they got a heart beat. 6 days later he was as declared brain dead.
The hospital has been protected by PREP act. The doctors are protected, pharmaceutical companies, government.. all protected. CICP was denied. I filled out the VAERS report because the doctors didn’t. (They all suspected the clots were from JJ, every single doctor I talked to). But I was brushed under the rug.
But who is protecting me and my late husband? Who is helping me?
No one.